E. Ongini

The non-xanthine heterocyclic compound SCH 58261 is a new potent and selective A2a adenosine receptor antagonist.

Cristina Zocchi, E. Ongini, Andrea Conti et al. · Journal of Pharmacology and Experimental Therapeutics · 1996 · 197 citations

Comparison of CGS 15943, ZM 241385 and SCH 58261 as antagonists at human adenosine receptors

E. Ongini, Silvio Dionisotti, Stefania Gessi et al. · Naunyn-Schmiedeberg s Archives of Pharmacology · 1999 · 185 citations · Full text

Molecular Pharmacology, Signal Transduction, Molecular Physiology +13

Antagonism of adenosine A2A receptors underlies the behavioural activating effect of caffeine and is associated with reduced expression of messenger RNA for NGFI-A and NGFI-B in caudate–putamen and nucleus accumbens

Per Svenningsson, George G. Nomikos, E. Ongini et al. · Neuroscience · 1997 · 170 citations

Molecular Pharmacology, Signal Transduction, Molecular Physiology +14

3H-SCH 23390 binding sites in the rat substantia nigra: Evidence for a presynaptic localization and innervation by dopamine

M.L. Porceddu, Osvaldo Giorgi, E. Ongini et al. · Life Sciences · 1986 · 93 citations

Presynaptic Localization, Neurophysiology, Neuroanatomy +15

Differential effects of dopamine D-1 and D-2 receptor antagonist antipsychotics on sleep-wake patterns in the rat.

E. Ongini, E. Bonizzoni, Nives Ferri et al. · Journal of Pharmacology and Experimental Therapeutics · 1993 · 88 citations